Clinical Trials Logo
  1. Home
  2. Peritoneal Metastases
  3. NCT04083547
  4. Details
NCT04083547 Clinical Trial

Circulating Tumour Cells in Patients With Peritoneal Metastases

Peritoneal Metastases Clinical Trial

Official title:
Cirkulerande Tumörceller Hos Patienter Med Bukhinnespridda tumörer

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04083547
Other study ID # CTC study
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 17, 2017
Est. completion date November 1, 2020

Study information
Verified date November 2020
Source Uppsala University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to evaluate the prognostic value of circulating tumour cells (CTC) in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy due to gastrointestinal cancers that have spread to the peritoneum.

Description:

CTCs har extracted by way of a new method at baseline, during surgery, and postoperatively. The occurence of such CTCs will be investigated for prognostic evaluation. Patients will be follow-up by Clinical routine. Disease recurrence and overall survival will be the endpoint used.

Recruitment information / eligibility
Status Completed
Enrollment 114
Est. completion date November 1, 2020
Est. primary completion date October 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Peritoneal metastases being treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy Exclusion Criteria: - None

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• iCellate
New method of circulating tumour cell detection and capture.

Locations
Country Name City State
Sweden Akademiska Sjukhuset (Uppsala University hospital) Uppsala

Sponsors (1)
Lead Sponsor Collaborator
Uppsala University

Country where clinical trial is conducted

Sweden, 

Outcome
Type Measure Description Time frame Safety issue
Primary Prognostic value Prediction of survival and recurrence according to the occurrence of CTCs. 2 year.
See also
  Status Clinical Trial Phase
Recruiting NCT03422432 - Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases N/A
Not yet recruiting NCT06295094 - The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. Phase 2
Recruiting NCT05056389 - Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) Phase 1
Withdrawn NCT03682744 - CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) Phase 1
Recruiting NCT06367270 - The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies Phase 2
Recruiting NCT05623787 - Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms N/A
Not yet recruiting NCT05095467 - HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction Phase 2
Recruiting NCT06216561 - Intraperitoneal LSTA1 in CRS-HIPEC Phase 1
Recruiting NCT05277766 - Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer Phase 1
Not yet recruiting NCT05318794 - Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer Phase 2
Completed NCT05665257 - Feasibility of Preoperative Inspiratory Muscle Training for Patients With Peritoneal Metastases N/A
Terminated NCT05581719 - A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy Phase 1/Phase 2
Recruiting NCT05379790 - Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin Phase 1
Recruiting NCT05204173 - Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis Phase 2
Recruiting NCT04956068 - PIPAC for Peritoneal Metastases Phase 1
Recruiting NCT04861558 - Efficacy of Hyperthermic Intraperitoneal Chemotherapy Phase 3
Recruiting NCT05340569 - Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma. N/A
Recruiting NCT03834272 - Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies Phase 1/Phase 2
Completed NCT03733184 - Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal Metastases
Recruiting NCT06046963 - Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites Phase 2